Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Other Operating Expenses (2022 - 2025)

Historic Other Operating Expenses for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $26.7 million.

  • Axsome Therapeutics' Other Operating Expenses rose 102.14% to $26.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.6 million, marking a year-over-year decrease of 2815.85%. This contributed to the annual value of $67.8 million for FY2024, which is 1664.13% down from last year.
  • As of Q3 2025, Axsome Therapeutics' Other Operating Expenses stood at $26.7 million, which was up 102.14% from $6.9 million recorded in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' Other Operating Expenses peaked at $52.2 million during Q4 2023, and registered a low of -$45.3 million during Q3 2022.
  • Moreover, its 4-year median value for Other Operating Expenses was $9.9 million (2023), whereas its average is $10.2 million.
  • In the last 5 years, Axsome Therapeutics' Other Operating Expenses surged by 9017006.52% in 2023 and then crashed by 5572.88% in 2024.
  • Over the past 4 years, Axsome Therapeutics' Other Operating Expenses (Quarter) stood at -$57946.0 in 2022, then skyrocketed by 90170.07% to $52.2 million in 2023, then plummeted by 55.73% to $23.1 million in 2024, then rose by 15.57% to $26.7 million in 2025.
  • Its Other Operating Expenses was $26.7 million in Q3 2025, compared to $6.9 million in Q2 2025 and $12.9 million in Q1 2025.